Related Experiment Video

Updated: Aug 14, 2026

Real-time Digital Imaging of Leukocyte-endothelial Interaction in Ischemia-reperfusion Injury (IRI) of the Rat Cremaster Muscle
15:07

Real-time Digital Imaging of Leukocyte-endothelial Interaction in Ischemia-reperfusion Injury (IRI) of the Rat Cremaster Muscle

Published on: August 5, 2012

C-reactive protein and atherothrombosis

M B Pepys1, G M Hirschfield

  • 1Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine, Royal Free and University College Medical School, London, UK. m.pepys@rfc.ucl.ac.uk

Italian Heart Journal : Official Journal of the Italian Federation of Cardiology
|April 18, 2001
PubMed

Insights

C-reactive protein (CRP) levels predict cardiovascular events and outcomes after heart attack, highlighting inflammation's role in atherosclerosis. CRP may directly contribute to disease development by binding to lipoproteins and activating complement.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Biochemistry

Background:

  • C-reactive protein (CRP) is a key systemic marker of inflammation.
  • Elevated CRP levels are linked to atherothrombotic events and outcomes post-myocardial infarction.
  • Inflammation plays a critical role in the development and complications of atherosclerosis.

Purpose of the Study:

  • To investigate the potential pathogenetic role of CRP in atherosclerosis.
  • To explore CRP's binding specificities and its interaction with cellular components.
  • To provide a basis for developing therapeutic strategies targeting CRP.

Main Methods:

  • Analysis of circulating CRP concentrations.
  • Examination of CRP binding to low-density lipoproteins (modified and unmodified).
  • Assessment of CRP interaction with damaged and dead cells.
  • Evaluation of complement activation by bound CRP.
  • Detection of CRP presence in atherosclerotic and myocardial infarction lesions.

Main Results:

  • Circulating CRP levels significantly predict atherothrombotic events and outcomes.
  • CRP binds to low-density lipoproteins and modified low-density lipoproteins.
  • CRP binds to damaged and dead cells.
  • Bound CRP activates the complement system.
  • CRP is present in atheroma and myocardial infarction lesions.

Conclusions:

  • CRP's predictive value for cardiovascular events underscores inflammation's role in atherosclerosis.
  • CRP's binding properties and complement-activating capacity suggest a direct pathogenetic role.
  • Targeting CRP-ligand interactions presents a potential therapeutic avenue for atherosclerosis.

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...